On May 15, 2018, the FDA in the United States approved Retacrit , which is a biosimilar of epoeitin alpha. This is a biosimilar competitor to Epogen/Procrit. It is considered appropriate treatment of anemia related to chronic kidney disease, chemotherapy, or the use of Zidovudine in HIV. It can also be used perioperatively for patient who cannot accept ref blood cell transfusions. The Data included extensive structural and functional characterization, animal safety studies, human pharmacokinetics and pharmacodynamic data as well as human immunogenicity studies.
Recent article published in the Journal of American medical association, United States prevented services task force issued updated recommendations on PSA testing for prostate cancer. When looking at the benefits versus the hormones a PSA-based screening, the committee concluded the following
Medications 55-69 years old, the decision undergo periodic PSA-based screening for prostate cancer should be individualized and include a discussion of the potential benefits and harms screening
Screening offers a potential benefit of reducing the chance of death from prostate cancer in some men.
Harms of screening include additional testing and possible prostate biopsy as a result of false positives, over diagnosis and overtreatment as well as treatment associated complications including incontinence and erectile dysfunction
Factors to be considered include family history, rates, ethnicity, medical comorbidities, as well as patient’s personal values and believes about diagnoses and intervention
In patients older than 7 years old, the task force recommended against PSAP screening
In this video, Dr Bristow discusses the role of germline and somatic mutations in prostate cancer.
Great review on the recent publication of the CELESTIAL trial where cabozantinib was compared to placebo in advanced hepatocellular carcinoma
News From PSMG
The latest news at Pacific Shores Medical Group
Disclaimer: This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, Pacific Shores Medical Group provides general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. Pacific Shores Medical Group is not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site.